ClinicalTrials.gg
RecruitingNCT04931160BRAISES-DiaPSSUpdated Jun 26, 2026

B-dependant Rare AutoImmune diseaSES - Cohort of Patients With Suspected Diagnosis of Primitive Sjögren Syndrome

An interventional study of Blood, fluid, sells and urine samples in Sjogren's Syndrome, sponsored by University Hospital, Brest. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by University Hospital, Brest · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Feb 2020; still recruiting 6 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Sjogren's Syndrome with a site in France — 18 open to participants now, 25 under way, 7 of them phase 3. Sjogren's Syndrome · France.

Planned enrollment
Largest of 40
1,000 · median 169
Started
2020
with 6 others
No phase
12 of 58
5 open now
Primary completion
2035-02
later than 24 of 24 live
Registered
18th of 58
by date
Lead sponsor
5 of 58
University Hospital, Brest

Among the 58 studies in Sjogren's Syndrome with a site in France, this one has the largest planned enrollment of the 40 interventional ones that give a count, is one of 7 that started in 2020, is one of 12 with no phase, reaches primary completion later than 24 of the 24 other live ones, and was the 18th registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

18 of the 58 studies in Sjogren's Syndrome with a site in France are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Sjogren's Syndrome with a site in France, or all of them as a file.
02

Study summary

The objectif is to study the diagnosis performance of the different classification criteria in reference to the gold standard consisting of the diagnosis made by expert doctors after standardized assessment, of pSS (primary Sjogren syndrome)

Read the detailed description

The formation of this patient is single-center prospective intervention. It consists of collecting data from patients suspected of pSS from standardized biological clinical data and imaging examination and additional pathology.

  • Sjögren patients will be followed at inclusion, 2y, 3y, 4y, 6y, 8y and 10 years. Blood, fluid, sells and urine samples will be collected at inclusion, 4y et 10y.
  • Non-Sjögren controls will be followed at inclusion and 4y and samples will be collected at the same visits.
03

Conditions studied

  • Sjogren's Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Major patient
  • Suspicion of SSp (clinical or biological criteria, i.e. dry eye or oral syndrome, arthritis, parotidomegaly, neuropathy, kidney or lung disease...)
  • Patient affiliated with Social Security
  • Patient who has signed written

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate
  • Pregnant and lactating woman
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Active comparator
    Sjögren patients

    patients diagnosed Sjögren

    Other: Blood, fluid, sells and urine samples

  • Other
    Non-Sjögren witnesses

    patients diagnosed no Sjögren

    Other: Blood, fluid, sells and urine samples

Interventions

  • OtherBlood, fluid, sells and urine samples

    Blood, fluid, sells and urine samples will be collected.

06

What researchers measure

Primary outcomes

  1. Description specificity of different classification criteria FOR sJOGREN (EULAR/ACR 2019, european criteria)

    Specificity of different classification criteria, the standard gold being the diagnosis obtained by consensus of expert doctors after standardized assessment.

    Time frame: Inclusion

Secondary outcomes

  1. Number of patients with different manifestation including in the ESSDAI (Eular Sjögren Syndrome Disease Activity index), gold standard to measure

    number of patients wit arthritis of more than 6 joints, parotidomegaly, intertitial lung disease

    Time frame: 10 years

  2. Number of patients with rheumatological manifestations

    number of patients wit arthritis of more than 6 joints, parotidomegaly, intertitial lung disease

    Time frame: 10 years

  3. Number of patients with dermatological manifestations

    number of patients wit arthritis of more than 6 joints, parotidomegaly, intertitial lung disease

    Time frame: 10 years

  4. Description diagnostic performance of new tests

    after evaluation of all différents test performed added to the classical items of the ACR 2017: ie ultrasound parenchymal abnormalities, sub population of B cells....

    Time frame: 10 years

  5. Disease evolution criteria

    modification of the ESSDAI at each visit

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for Feb 2035, 180 months after the start.

Of 39 non-industry interventional studies with no phase under Sjogren's Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's planned 180 months is above that.

Counting every sponsor, half of 44 studies reached it within 18 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2019
First posted
Jun 18, 2021
StartActual
Feb 10, 2020
Primary completionEst.
Feb 10, 2035
CompletionEst.
Feb 10, 2035
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04931160
Responsible party
Sponsor
First posted
Jun 18, 2021
Start date
Feb 10, 2020
Primary completion
Feb 10, 2035 (estimated)
Completion
Feb 10, 2035 (estimated)
Last update
Jun 26, 2026

Study contacts

Valérie Devauchelle, MD,PhD
Contact
valerie.devauchelle-pensec@chu-brest.fr
33 (0) 2 98 34 72 64
Valérie Devauchelle
principal investigator · CHRU BREST

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion